BioSpace News Archive

Financing will support future studies of lead program BCA101, currently in Phase 1/1b clinical development in head and neck cancer, and pipeline growth.

Reata Pharmaceuticals, Inc. announced that management will participate in the Barclays Global Healthcare Conference held next week, March 14-16, in Miami, Florida.

Axogen, Inc. today announced the appointment of Marc Began as Executive Vice President.

Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided recent business highlights.

MediWound Ltd., a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, announced the appointment of Barry Wolfenson as Executive Vice President of Strategy & Corporate Development.

Chemomab Therapeutics Ltd. today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.

Immix Biopharma, Inc. and its subsidiary Nexcella, Inc. (“Nexcella”) today announced that Ilya Rachman, M.D., Ph.D., ImmixBio Chief Executive Officer, and Gabriel Morris, Nexcella President, will discuss recent positive NXC-201 clinical data in AL Amyloidosis and Multiple Myeloma in a fireside chat at the 35th Annual Roth Conference on Tuesday, March 14, 2023 at 10:30 a.m. PT.

OrthoPediatrics Corp. a company focused exclusively on advancing the field of pediatric orthopedics, announced it was recently named one of the 2023 Best Places to Work in Indiana.

Hummingbird Bioscience, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today announced that Hummingbird Bioscience has exercised its option to license in the first-in-human (FIH) clinical trial results of HMBD-001, a differentiated and potentially best-in-class HER3-targeting antibody.

Octapharma USA presented research at the American Academy of Allergy, Asthma & Immunology Annual Meeting evaluating the efficacy and safety of cutaquig® infusions at higher infusion parameters, potentially offering greater dosing flexibility for patients.